The next wave of coronavirus vaccine research should be a reality

The next wave of coronavirus vaccine research should be a reality

COVID-19 vaccinations for young children now expected to start later this year

A doctor says the next wave of coronavirus vaccine research should be a reality

A new vaccine is being developed to protect children aged two and younger from coronavirus.

The vaccine, which is being developed by GlaxoSmithKline, is based on work done by the U.S. Army, the U.S. Department of Defense, the National Institutes of Health and multiple vaccine manufacturers over almost a century.

It was made earlier in spring in a lab in England.

The vaccine is designed to mimic the immune system response to a virus that causes the common cold, but on the first day of exposure.

The second day is known as a “window period,” when the body can get a head start and protect itself against a virus by pumping large amounts of immune cells into the body.

The research is being led by Professor Andrew Martin of Queen Mary University of London, and is being funded by the Innovative Medicines Initiative (IMI).

More than 30 pharmaceutical companies, including GlaxoSmithKline, are involved in the project.

The IMI has set a target of £14 million (14 million euros) for the project, which will be funded by the UK and the European Union over the next three years, with the funds to be used to research, develop and investigate the immune response and protective antibodies to coronavirus, as well as develop a vaccine.

The IMI has established the Accelerated Development Group (ADG) to bring vaccine development to the forefront of the coronavirus pandemic.

Its aim is to speed the development of vaccines and generate data to help the global immune response to this new virus.

A vaccine has been selected to make use of an experimental antibody that inhibits coronavirus infection, which is being developed by GlaxoSmithKline.

It will be the first coronavirus vaccine to go through a phase 1 trial, which tests its safety and immunological efficacy.

The company said it was confident of achieving an active-controlled, double-blind trial.

An additional safety trial is also being prepared as an ancillary study, which will look at

Leave a Comment